Abstract
Monitoring of biological treatment efficacy for psoriasis is based on clinical evaluation and patient's quality of life. However, long-term correlation between Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) in real life has not been studied in patients treated with ustekinumab. All patients with psoriasis treated with ustekinumab at our department were included (n = 120) in this study. Correlation analyses between the change in PASI and DLQI and the individual subquestions in DLQI were performed using Spearman's rank correlation coefficient. A correlation value of 0.57 (p-value <0.001) and 0.45 (p-value < 0.001) between PASI and DLQI were found in the period baseline - 4 months and baseline - 12 months, respectively. In DLQI subquestions, the greatest association was found for the questions on "Symptoms and feelings". Objective improvements in the severity of psoriasis were weakly to moderately associated with improvements in quality of life in patients with psoriasis treated with ustekinumab.
| Original language | English |
|---|---|
| Journal | Acta Dermato-Venereologica |
| Volume | 98 |
| Issue number | 3 |
| Pages (from-to) | 335-339 |
| Number of pages | 5 |
| ISSN | 0001-5555 |
| DOIs | |
| Publication status | Published - 2018 |
Keywords
- Adult
- Denmark
- Dermatologic Agents/adverse effects
- Female
- Humans
- Male
- Middle Aged
- Prospective Studies
- Psoriasis/diagnosis
- Quality of Life
- Registries
- Remission Induction
- Severity of Illness Index
- Skin/drug effects
- Surveys and Questionnaires
- Time Factors
- Treatment Outcome
- Ustekinumab/adverse effects